PDCD1 and colorectal carcinoma: The breakthrough for immunotherapy in CRC started with a landmark trial in 2012 that was sponsored by Bristol-Myers Squibb, the company that developed the anti-programmed cell death protein 1 (anti-PD-1) antibody Nivolumab.